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Dr ShiraishiObjective: Multidrug-resistant tuberculosis remains a significant health problem.
The best available treatment for multidrug-resistant tuberculosis is the combination
of pulmonary resection and antituberculous chemotherapy. We herein report the
results of pulmonary resection combined with chemotherapy for multidrug-resistant
tuberculosis at our institution during the years 2000 through 2002.
Methods: Between 1983 and 2002, 87 patients underwent 95 pulmonary resections
for multidrug-resistant tuberculosis. Of these, the 30 (34%) patients operated on
from January 1, 2000, to December 31, 2002, are reviewed in the present study. All
patients were maintained on multidrug regimens preoperatively and postoperatively.
Indications for surgical intervention included persistently positive sputum and a
high risk of relapse. Thirty-three pulmonary resections were performed, consisting
of pneumonectomy (n 12), lobectomy (n 17), and segmentectomy (n 4). The
bronchial stump was reinforced with a latissimus dorsi muscle flap in 29 resections.
Results: There was no operative mortality. Bronchopleural fistulas occurred in 2
patients. Five patients had a space problem. All patients attained sputum-negative
status after the operation. Relapse occurred in 3 patients: 2 had a relapse at the
bronchial stump, and the remaining patient had a relapse in the postlobectomy
space. One late death occurred. Of the 29 survivors, 27 (93%) were free from
disease, with a median follow-up of 24 months (range, 8-47 months).
Conclusions: An increasing number of patients with multidrug-resistant tuberculosis
are requiring resectional surgery in the 21st century. Pulmonary resection combined
with chemotherapy achieves high cure rates with acceptable morbidity and remains
the treatment of choice for multidrug-resistant tuberculosis.
Pulmonary tuberculosis remains a global threat. The emergence ofmultidrug-resistant strains (ie, strains resistant to at least isoniazid andrifampin [INN: rifampicin])1 is an especially significant health prob-lem.2,3 Multidrug-resistant tuberculosis is difficult to treat, and itsmanagement thus requires expertise. Medical treatment with first- andsecond-line antituberculous drugs does not achieve satisfactory out-
comes.4 Therefore resection of cavitary lesions or destroyed lobes, which harbor
large numbers of bacilli, has been advocated to improve the efficacy of medical
treatment.5-10 Although the results of medical treatment of multidrug-resistant
tuberculosis have improved since the introduction of fluoroquinolone antibiot-
ics,11,12 current fluoroquinolone-containing regimens are not panaceas. No random-
ized controlled studies have been conducted to compare the results of chemotherapy
alone with the results of pulmonary resection combined with chemotherapy.13
Retrospective studies during the fluoroquinolone era, however, have demonstrated
The Journal of Thoracic and Cardiovascular Surgery ● Volume 128, Number 4 523
General Thoracic Surgery Shiraishi et al
G
TSthat surgical treatment plus chemotherapy achieves more
favorable results than chemotherapy alone.12,14 The combi-
nation of pulmonary resection and antituberculous chemo-
therapy, when feasible, thus represents the best available
treatment of multidrug-resistant tuberculosis.
Our institution was established as a sanatorium in the late
1940s and is recognized as a major center for pulmonary
tuberculosis in Japan. We have performed pulmonary re-
sections since 1983 on patients with multidrug-resistant
tuberculosis. As a result of a recent increase in the number
of referrals, patients operated on after January 1, 2000,
comprise one third of our entire surgical series. Further-
more, during this period, we have been using newer fluo-
roquinolones in multidrug treatment regimens and perform-
ing muscle flap reinforcement of the bronchial stump in
almost all of our pulmonary resections. We herein report the
results of pulmonary resection combined with chemother-
apy for multidrug-resistant tuberculosis at our institution
during the years 2000 through 2002.
Patients and Methods
Between January 1983 and December 2002, 87 patients underwent
95 pulmonary resections for multidrug-resistant tuberculosis at
Fukujuji Hospital. Of these 87 patients, the 30 (34%) patients who
were operated on from January 1, 2000, to December 31, 2002, are
reviewed in the present study. There were 21 (70%) male patients
and 9 (30%) female patients. Age at the time of the operation
ranged from 22 to 64 years (median, 48 years). None of the
patients were immunocompromised. Twelve patients had diabetes.
Sputum smears and sputum cultures were performed on admission.
Drug susceptibility testing was routinely performed on positive
cultures in our laboratory. Bronchoscopy was done in some cases
to rule out contralateral disease, coexisting malignancies, or both.
All patients had received antituberculous chemotherapy at the
referral hospitals or at our institution, and at the time of admission,
were shedding strains resistant to a median of 6 drugs (range, 2-9
drugs), including isoniazid and rifampin. Multidrug regimens, with a
median of 4 drugs (range, 3-6 drugs), were initiated in all patients.
Drugs included in the regimens were chosen on the basis of drug
susceptibility testing results. When the regimens being used in the
referral hospitals were appropriate, those regimens were continued.
TABLE 1. Types of pulmonary resection
Procedure Right Left Total
Completion pneumonectomy 1 0 1
Pneumonectomy 5 6 11
Upper and middle lobectomy 1 0 1
Upper lobectomy with segmentectomy* 4 1 5
Upper lobectomy 5 5 10
Lower lobectomy 0 1 1
Segmentectomy 1 3 4
Total 17 16 33
*Upper lobectomy with resection of superior segment of the lower lobe.Fluoroquinolones were included in the regimens of 24 (80%) patients.
524 The Journal of Thoracic and Cardiovascular Surgery ● OctoEighteen patients, 5 patients, and 1 patient received levofloxacin,
sparfloxacin, and ciprofloxacin, respectively. Other drugs used in-
cluded ethambutol, streptomycin, kanamycin, enviomycin, pyrazin-
amide, ethionamide, para-aminosalicylic acid, cycloserine, and thio-
acetazone. Patients were treated with multidrug regimens for at least
3 months. Resection of cavitary lesions or destroyed lobes was con-
sidered for those patients who had persistently positive sputum despite
chemotherapy. Among patients who had sputum conversion from
positive to negative in response to chemotherapy, surgical interven-
tion was considered for those at high risk of relapse on the basis of
drug resistance patterns, radiographic findings, or both.
Preoperative studies included chest roentgenography, com-
puted tomographic scans of the chest, pulmonary function tests,
arterial blood gas analysis, and a quantitative perfusion scan. To be
eligible for surgical intervention, patients had to have sufficient
pulmonary reserve to tolerate pulmonary resection and have le-
sions predominantly localized to one lung. Scattered nodular le-
sions on the contralateral side were acceptable; indeed, only 6
patients had their tuberculosis limited entirely to one side, with the
opposite side totally intact. When patients had cavitary lesions on
both sides, staged bilateral resections were applied if patients could
tolerate bilateral procedures. Thirty-three pulmonary resections
were performed (Table 1). Three patients underwent staged mul-
tiple resections. One was a patient who had undergone a right
upper lobectomy with segmentectomy and who subsequently un-
derwent a right completion pneumonectomy for recurrent disease.
The remaining 2 patients had staged bilateral resections: a left
upper lobectomy and a right upper lobectomy in 1 patient and a
right upper lobectomy and resection of 2 segments of the left lung
in the other patient.
Operations were performed after achievement of general anes-
thesia and epidural anesthesia with the use of a double-lumen
endobronchial tube. After induction of anesthesia, we performed a
posterolateral thoracotomy. In patients with dense adhesions, we
chose extrapleural dissection to keep their cavities intact. During
the course of extrapleural dissection, we used electrocautery,
bipolar scissors (PowerStar Bipolar Scissors; Ethicon Inc,
Somerville, NJ), or both to reduce blood loss.15 The bronchus was
divided and closed with staples (n  29) or sutures (n  4). The
bronchial stump was reinforced with a latissimus dorsi muscle flap
in 29 resections and with a pericardial fat pad in one resection.
Bronchial stump reinforcement was not performed in 3 segmental
resections. Our technique for constructing a latissimus dorsi mus-
cle flap was the same as the technique described by Pairolero and
associates.16 We meticulously used electrocautery and an argon
beam coagulator to stop all internal bleeding. The pleural cavity
was irrigated with at least 10 L of saline and povidone iodine, and
the chest was then drained of fluid.
After the operation, all patients were maintained on multidrug
regimens, generally the same as their preoperative regimens. Du-
ration of postoperative chemotherapy ranged from 6 to 30 months
(median, 18 months). Patients were followed up through Decem-
ber 31, 2003, with a median follow-up of 24 months (range, 8-47
months). Operative mortality included all deaths clearly related to
the operation, regardless of the postoperative interval. All cases of
bronchopleural fistula or empyema occurring subsequent to the
date of the operation were considered postoperative complications.
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Ten (33%) patients had positive sputum at the time of the
operation. Surgical operations were equally divided be-
tween the right side and the left side (Table 1). Operating
time ranged from 140 to 623 minutes (median, 270 min-
utes). Median intraoperative blood loss was 180 mL (range,
10-1330 mL). No spillage of the contents of cavities into the
operative field occurred in any patient. There was no oper-
ative mortality. Nine (30%) patients had a total of 10
complications (Table 2).
Two patients had bronchopleural fistulas; both had dia-
betes and positive sputum at the time of the operation. The
first patient had strains resistant to 7 drugs and underwent a
right pneumonectomy with latissimus dorsi muscle flap. His
sputum culture, which was negative after the operation,
turned positive 3 months after the operation. However, no
lesions were identified in the left lung, and the bronchial
stump seemed intact. Two months later, bronchial stump
disruption occurred, and lavage fluid from the bronchial
stump was positive for tuberculosis. His strains had ac-
quired resistance to 2 additional drugs used in the regimen
by this time. He underwent an open-window thoracostomy.
Over time, the muscle flap covering the bronchial stump
was gradually eroded by the uncontrollable tuberculous
infection, and a bronchopleural fistula finally developed 12
months after the initial operation, resulting in tuberculous
empyema. The second patient had strains resistant to 8
drugs, and underwent a left upper lobectomy with stapling
technique. He spit up the staples 21 months after the oper-
ation, and his sputum turned positive at that time. His strains
had acquired resistance to 2 additional drugs used in the
regimen by this time. Bronchopleural fistula and empyema
occurred 2 months afterward. He then underwent an open-
window thoracostomy.
Among the 5 patients in whom a space problem oc-
curred, 3 patients had undergone an upper lobectomy with
segmentectomy, and 1 patient had undergone an upper and
middle lobectomy. The operative records of these 4 patients
contained comments that the surgeons had great difficulty
dissecting dense pleural adhesions and that the remaining
lobes were relatively small and stiff. The fifth patient had
undergone resections of both the anterior segment of the left
upper lobe and the superior segment of the left lower lobe.
The space problems in all 5 patients were treated with
thoracoplasty.
All 30 study patients attained negative sputum status
after the operation. Relapse of multidrug-resistant tubercu-
losis occurred in 3 patients. Two patients had a relapse at the
bronchial stump 3 and 21 months postoperatively, respec-
tively, as mentioned above. The third patient had a relapse
in the postlobectomy space. This patient underwent a right
upper lobectomy with segmentectomy, followed by a tho-
racoplasty for a space problem 1 month later. After thora-
The Journal of Thoracicoplasty, 4 months after the initial operation, this patient
had a space problem again. A computed tomographic scan
of the chest showed a small cavity in the right lower lobe
that had perforated into the space. The pleural fluid col-
lected from the space was positive for tuberculosis. The
patient was treated with completion pneumonectomy after 6
months of open drainage, and negative conversion was
achieved. One late death resulted from cerebral infarction 8
months postoperatively. Twenty-seven (93%) of the 29 sur-
vivors were free from disease at the time of follow-up.
Discussion
The recent emergence of tubercle bacilli resistant to both
isoniazid and rifampin, which are the most potent antitu-
berculous drugs, represents an emerging global problem.2,3
These multidrug-resistant strains of tuberculosis are of great
concern.1 Medical treatment of multidrug-resistant tubercu-
losis is not satisfactory, even with long-term aggressive and
intensive multidrug regimens, including first- and second-
line drugs.4 Adjunctive surgical treatment has been advo-
cated to improve the efficacy of medical treatment.5-10 The
purpose of such surgical treatment is to reduce the bacterial
burden by resecting cavitary lesions or destroyed lobes. The
introduction of fluoroquinolone antibiotics has raised hopes
of improving the currently dismal prognosis for multidrug-
resistant tuberculosis. However, antituberculous chemother-
apy containing fluoroquinolones are not panaceas. Resec-
tional surgery continues to have an important adjunctive
role in the management of multidrug-resistant tuberculosis.
In the year 2000, our hospital was certified as one of the
key centers for treating multidrug-resistant tuberculosis in
Japan. This certification has brought about an increasing
number of referrals for treatment of patients with multidrug-
resistant tuberculosis and has altered the temporal distribu-
tion of patients in our multidrug-resistant tuberculosis sur-
gical series. Of the 87 patients treated surgically over the
20-year period from 1983 through 2002, one third (30
patients) were operated on from 2000 through 2002. The
present study focused on these 30 patients, who received our
most current surgical and medical treatment regimen for
multidrug-resistant tuberculosis. During this period, we
have been using more potent fluoroquinolones in our mul-




Bronchopleural fistula with empyema 2 (6)
Space problem 5 (15)
Prolonged air leak 2 (6)
Chylothorax 1 (3)tidrug regimens to improve the efficacy of medical treat-
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prevent bronchial stump problems and space problems.
Our results were basically in line with those of previous
studies.7-10 Patients were shedding strains resistant to a
median of 6 drugs, including isoniazid and rifampin, and
they had been treated with multidrug regimens containing a
median of 4 drugs for at least 3 months before the operation.
Indications for resectional operations were (1) persistent
positive sputum despite chemotherapy or (2) high risk of
relapse, even after negative conversion was achieved by
means of chemotherapy. Dissection of dense pleural adhe-
sions was performed extrapleurally.17 Operative mortality
was zero, but morbidity was a problem. Postoperative che-
motherapy was continued for a median of 18 months. Al-
though the follow-up period is relatively short, pulmonary
resection has achieved high cure rates.
The distinctive features of the present study included active
use of levofloxacin in the multidrug regimens and a higher
incidence of bronchopleural fistulas and space problems than
reported in previous studies. This study included only patients
operated on after January 1, 2000. As a result, levofloxacin,
which was used in 60% of the patients, was the most com-
monly used fluoroquinolone in the multidrug regimens. In the
study by Chan and associates,14 which reviewed 205 patients
treated between 1984 and 1998, ofloxacin was used in 124
patients, and levofloxacin was used in only 9 patients. In a
study from Turkey, ofloxacin was the fluoroquinolone in-
cluded in the regimens.12 Levofloxacin has been reported to be
more efficacious than ofloxacin in the treatment of multidrug-
resistant tuberculosis.18 In the present study one third of the
patients had positive sputum at the time of the operation. This
figure is lower than what has been previously reported. In the
study by Pomerantz and associates,10 one half of the patients
had positive sputum at the time of the operation. Our higher
preoperative negative conversion rate might be in part caused
by more patients having been treated with levofloxacin-
containing regimens.
Despite the use of a latissimus dorsi muscle flap, 2 (6%)
patients had bronchopleural fistulas in the present study.
This fistula rate was higher than the rate reported in previ-
ous studies. In the study by Pomerantz and associates,10
only 5 bronchopleural fistulas occurred after 180 pulmonary
resections. In a report from South Africa, 2 bronchial stump
fistulas occurred in 35 patients undergoing pneumonec-
tomy, and no fistulas occurred after lobectomies.8 We be-
lieve that the development of fistulas in our study was not
caused by problems with our surgical technique. The fistu-
las occurred late after the operation and were preceded by a
relapse at the bronchial stump. Both patients initially
achieved negative conversion after the operation, but their
strains at the time of relapse had acquired resistance to 2
additional drugs used in the regimens. We suspect that the
bronchial stump might have been contaminated with tuber-
526 The Journal of Thoracic and Cardiovascular Surgery ● Octocle bacilli at the time of the operation and that the infection
could not be controlled with postoperative intensive chemo-
therapy, resulting in bronchial stump disruption. Even the
latissimus dorsi muscle flap could not protect the stump
against uncontrollable tuberculous infection. We fully agree
with the following criterion for pulmonary resection pro-
posed by Iseman and coworkers5: “sufficient drug activity
to diminish the mycobacterial burden enough to facilitate
probable healing of the bronchial stump.”
We also encountered space problems, even with the use
of a latissimus dorsi muscle flap. Four of the 5 space
problems occurred after procedures that were more exten-
sive than lobectomy, such as bilobectomy or lobectomy
with segmentectomy. Furthermore, in these 4 patients we
encountered great difficulty dissecting dense pleural adhe-
sions. As a result, the remaining lobes were too small and
too stiff to fill the pleural space. In these cases putting the
latissimus dorsi muscle flap into the pleural space might not
have been sufficient to obliterate the entire residual space. A
better technique for harvesting the flap and covering both
the bronchial stump and the raw surface of the remaining
lung needs to be developed. Tailored thoracoplasty might be
indicated to achieve further obliteration of the residual
space. Although pneumonectomy produces a cleaner oper-
ation, we cannot conclude that pneumonectomy would have
been the procedure of choice for these patients. Unless the
lung is totally destroyed, it is better to leave as much lung
parenchyma as possible without jeopardizing the complete-
ness of the removal of major lesions to preserve pulmonary
functions.
This retrospective study has its limitations. It was not
possible to conduct a randomized controlled study to com-
pare the efficacy of surgical treatment plus chemotherapy
with the efficacy of chemotherapy alone. Therefore our
study was a single-arm study. The patients enrolled in this
study had already been selected as eligible for pulmonary
resection. We have achieved a 93% cure rate in our surgical
group to date, but this figure cannot be directly compared
with cure rates for study groups receiving chemotherapy
alone. Our current strategy for the management of multi-
drug-resistant tuberculosis is to perform pulmonary resec-
tion whenever indicated to augment the efficacy of medical
treatment. A group in Denver has taken the same strategy
and has achieved favorable results.5,14 In their recent report
the use of surgical intervention increased in frequency dur-
ing the course of their study period, and surgical resection
was performed on 83% of the patients treated during the last
5 years.14 Our results and previously reported results indi-
cate that patients with multidrug-resistant tuberculosis could
have a greater chance of being cured with the use of adju-
vant resectional surgery in combination with intensive med-
ical treatment.
ber 2004
Shiraishi et al General Thoracic Surgery
G
TSReferences
1. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl
J Med. 1993;329:784-91.
2. World Health Organization. Anti-tuberculosis drug resistance in the
world. Report no. 3. The WHO/IUATLD global project on anti-
tuberculosis drug resistance surveillance 1999-2002. Geneva: World
Health Organization; 2004.
3. Nachega JB, Chaisson RE. Tuberculosis drug resistance. A global
threat. Clin Infect Dis. 2003;36(suppl 1):S24-30.
4. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh
CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant
to isoniazid and rifampin. N Engl J Med. 1993;328:527-32.
5. Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention
in the treatment of pulmonary disease caused by drug-resistant Myco-
bacterium tuberculosis. Am Rev Respir Dis. 1990;141:623-5.
6. Pomerantz M, Madsen L, Goble M, Iseman M. Surgical management
of resistant mycobacterial tuberculosis and other mycobacterial pul-
monary infections. Ann Thorac Surg. 1991;52:1108-12.
7. Treasure RL, Seaworth BJ. Current role of surgery in Mycobacterium
tuberculosis. Ann Thorac Surg. 1995;59:1405-9.
8. Van Leuven M, De Groot M, Shean KP, Von Oppell UO, Willcox PA.
Pulmonary resection as an adjunct in the treatment of multiple drug-
resistant tuberculosis. Ann Thorac Surg. 1997;63:1368-73.
9. Sung S-W, Kang CH, Kim YT, Han SK, Shim Y-S, Kim JH. Surgery
increased the chance of cure in multi-drug resistant pulmonary tuber-
culosis. Eur J Cardiothorac Surg. 1999;16:187-93.
10. Pomerantz BJ, Cleveland JC Jr, Olson HK, Pomerantz M. Pulmonary
resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc
Surg. 2001;121:448-53.
11. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients
with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J
Tuberc Lung Dis. 1998;2:877-84.
12. Tahaoglu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, et al. The
treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med.
2001;345:170-4.
13. American Thoracic Society/Centers for Disease Control and Preven-
tion/Infectious Diseases Society of America. Treatment of tuberculo-
sis. Am J Respir Crit Care Med. 2003;167:603-62.
14. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh MN, Goble M, et al.
Treatment and outcome analysis of 205 patients with multidrug-resis-
tant tuberculosis. Am J Respir Crit Care Med. 2004;169:1103-9.
15. Shiraishi Y, Nakajima Y, Koyama A, Takasuna K, Katsuragi N,
Yoshida S. Morbidity and mortality after 94 extrapleural pneumonec-
tomies for empyema. Ann Thorac Surg. 2000;70:1202-6.
16. Pairolero PC, Arnold PG, Piehler JM. Intrathoracic transposition of
extrathoracic skeletal muscle. J Thorac Cardiovasc Surg. 1983;86:
809-17.
17. Brown J, Pomerantz M. Extrapleural pneumonectomy for tuberculosis.
Chest Surg Clin North Am. 1995;5:289-96.
18. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, et al.
Comparative roles of levofloxacin and ofloxacin in the treatment of
multidrug-resistant tuberculosis. Preliminary results of a retrospective
study from Hong Kong. Chest. 2003;124:1476-81.
Discussion
Dr Andrew A. Conlan (Worcester, Mass). Dr Shiraishi, I con-
gratulate you and your team on the very excellent surgical out-
come, especially disease control, and on the quality of your pre-
sentation. It is a retrospective study, if I take it correctly, and there
are 30 patients, 10 of whom were sputum positive coming to
surgical intervention and 20 who were judged to be at very high
risk of relapse, and therefore surgical intervention was added to
their treatment. An excellent disease-free status with an average
for a medium follow-up of 28 months is a great achievement.
It is hard to talk about multiple drug–resistant tuberculosis
without acknowledging the global problem, and it is staggering
that a third of the global population, 2 billion persons, have
The Journal of Thoracituberculosis, with 2 million of these thought have drug-resistant
tuberculosis. These costs are staggering. For example, to treat a
patient with normal tuberculosis is about $12,000 to bring them to
a sputum-negative state, and with multiple drug–resistant tubercu-
losis, it is about $200,000 per patient.
I was particularly impressed with the surgical management, and
I commend the early and prophylactic use of the extrapleural plane
for these very tough lobectomies and pneumonectomies. Likewise,
using the latissimus dorsi flap was a very good treatment inclusion.
I would like to ask a number of questions. You had 5 patients
with space problems. Interestingly, in your article you mentioned
that the surgeons noted tough operating conditions and also that
they noted small and inexpansile remaining lung. All of them had
resections greater than a lobe. Now this set of circumstances is a
classic endgame for a postresection space, and even though a
latissimus dorsi flap was put in, I wonder whether you have any
comment that if the surgeon recognized this whether he should not
have used additional flaps or even considered thoracoplasty at the
time of the resection because all of them went into the chronic
space, sequential operations, and ultimate thoracoplasty at a much
later date. What are your thoughts about that?
Dr Shiraishi. That is a good point. Actually, we encountered 5
patients with space problems. In 4 of the 5 patients, we had great
difficulty in dissecting dense pleural adhesions during surgical
intervention. Therefore the remaining lung was very small and
stiff, and it would be better to obliterate the whole space by means
of tailored thoracoplasty or a serratus muscle flap in addition to the
latissimus dorsi muscle, but I do not have a good answer for that
right now. Another option is that we would take out the whole lung
and do a pneumonectomy, but some patients had very poor pul-
monary reserve and could not tolerate a pneumonectomy. There-
fore we try to leave as much lung parenchyma as possible. We
avoid pneumonectomy and perform bilobectomy or lobectomy
with segmentectomy.
Dr Conlan. Certainly it is a matter of extreme surgical judg-
ment to pay homage to each of those things you mentioned.
Now your results have been incredibly good, the best. How-
ever, I wanted to, as we always do, ask you about the failures. You
said 2 of your failures occurred at the bronchial stump. Now I have
always had difficulty with this concept of the bronchial stump
being the point of failure because unless we have histopathology
and biopsy specimens from the bronchial stump that are positive
for acid-fast bacilli on stain or on culture, I do not regard it as the
primary source. The bronchial stump is broken down, and there-
fore it is a conduit, and when you wash it and get a positive wash,
you are retrieving fluid from the peribronchial space, the pleura, or
the parenchyma distal to it. Therefore I wonder whether you want
to comment on the bronchial stump being the prime source of
recurrence.
Dr Shiraishi. We had 2 relapses at the bronchial stump. One
patient had undergone a right pneumonectomy, and his sputum
became positive again 4 months after the operation. At that time,
his chest computed tomographic scan showed no lesions on the left
side, and the bronchial stump looked good. But 2 months later, we
checked the stump again and found that the stump was totally
disrupted. We could see the flap covering the stump. We washed
the stump, and the lavage fluid was positive for tuberculosis.
Therefore I conjectured that the relapse occurred at the stump.
c and Cardiovascular Surgery ● Volume 128, Number 4 527
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just define for us the residuals that you feel have the highest
bacillus or the highest tuberculosis population within them, and do
you identify high-risk residuals compared with low-risk residuals?
We are often in the position where we remove a destroyed lobe,
but we are aware that there are small nodular abnormalities in the
contralateral lung or the same lung. What type of lesions do you
designate as low risk, and also tell us which ones that you regard
as high risk.
Dr Shiraishi. As you know, the cavities or destroyed lobes are
at great risk for relapse, but small tiny nodules will not be.
Therefore you have to resect cavities or destroyed lobes, but you
can leave small nodules.
Dr Stephen D. Cassivi (Rochester, Minn). I appreciated your
presentation. Clearly this is a difficult problem, and your results
are very commendable.
I have just a very short question. It regards your postresectional
antimicrobial therapy and how you choose the length of time that
you are going to treat these patients. In your presentation, your
range was from 6 months to “upward.” How do you choose when
to stop antimicrobial therapy?
Dr Shiraishi. Basically, we try to keep patients on multidrug
regimens for at least 18 months after sputum conversion has been
achieved. Therefore if the patient has experienced negative con-528 The Journal of Thoracic and Cardiovascular Surgery ● Octopostoperative chemotherapy. Usually, we keep the patients on
chemotherapy for at least 18 months after the operation.
Dr Rajan Santosham (Chennai, India). I have one or two
comments to make. We do not resect multidrug-resistant tubercu-
losis unless it is for massive hemoptysis because we are very
worried about the outcome, and a large number of our patients
become worse off than when they started. They have empyema,
bronchopleural fistula, and space problems. But if there is resistant
tuberculosis and if it is cavitary, we still perform thoracoplasty,
which is very ideal for localized cavitary disease with persistent
organisms.
Dr Shiraishi. We sometimes do thoracoplasty for multidrug-
resistant patients. But on the basis of our experience, thoracoplasty
does not always show good results because sometimes it is difficult
to collapse the thick-walled cavities by means of thoracoplasty.
Therefore if the patient can tolerate pulmonary resection, you
should go for resection instead of thoracoplasty.
Dr Thomas M. Egan (Chapel Hill, NC). Congratulations on
outstanding results. How many of your patients had AIDS, and
what would be your recommendation for patients with HIV who
are infected with tuberculosis?
Dr Shiraishi. We do not have any HIV-positive patients in this
series. All patients were HIV-negative. Therefore I do not have aversion before the operation, we can shorten the duration of comment on treating HIV-positive patients.ber 2004
